



Five Prime Therapeutics, Inc.  
Investor Relations Department  
Two Corporate Dr, Suite 200  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### NASDAQ: FPRX <sup>1</sup>

|                      |  |
|----------------------|--|
| Last Trade:          | 28.06                                    |
| Trade Time:          | 4:00 PM ET<br>Friday, August<br>18, 2017 |
| Change:              | -0.44<br>(1.544%)                        |
| Day Range            | 27.17 - 29.04                            |
| 52-Week Range        | 25.97 - 60.98                            |
| Volume               | 333,976                                  |
| Market Cap.<br>(\$M) | 810.934                                  |
| Shares Out (M)       | 28.900                                   |

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immunoncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Thursday, August 17, 2017*  
[Five Prime Therapeutics Announces Addition of Bryan Irving, PhD, as Senior Vice President, Research](#)

*Tuesday, August 8, 2017*  
[Five Prime Announces Second Quarter 2017 Results and Provides Business Update](#)

*Wednesday, July 26, 2017*  
[Five Prime Therapeutics to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8](#)

*Monday, July 17, 2017*  
[Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development](#)

*Wednesday, June 21, 2017*  
[Five Prime Therapeutics Announces Lewis T. "Rusty" Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

### [Second Quarter Financial Results](#)

*Friday, February 24, 2017*  
[Annual Report \(10-K\)](#)

*Friday, March 31, 2017*  
[Definitive Proxy Statement](#)

*Tuesday, August 8, 2017*  
[Quarterly Report \(10-Q\)](#)

*Friday, May 5, 2017*  
[Quarterly Report \(10-Q\)](#)

*Friday, November 4, 2016*  
[Quarterly Report \(10-Q\)](#)